The earnings call reveals strong financial performance with significant revenue growth and profitability improvements, especially in key markets like Egypt and Saudi Arabia. However, challenges remain in certain areas such as operations in Sudan and the high advertising expenses. Overall, the positive aspects of the company's growth and strategic expansions outweigh the challenges.

Company Guidance

During the recent conference call, IDH provided guidance for the 2025 fiscal year, highlighting a strong first half performance. The company reported a 42% year-over-year increase in consolidated revenue, reaching EGP 3.5 billion, driven by a 10% rise in test volumes and a 29% increase in average revenue per test. The number of tests performed totaled nearly 20 million across four markets, with Egypt leading with a 43% revenue increase. The company also announced a cash dividend of $0.017 per share for the year ended December 31, 2024. Operational efficiency was emphasized, with a gross profit margin increase of 5 percentage points and an adjusted EBITDA margin expansion of 7 percentage points. IDH's strategy focuses on cost optimization, with cost of goods sold and SG&A expenses dropping by a combined 9 percentage points. The company maintains a strong liquidity position, supporting these strategic investments and shareholder value. For the full year of 2025, IDH anticipates a revenue growth of around 30% and an EBITDA margin exceeding 30%, thanks to proactive cost control efforts mitigating inflationary pressures in Egypt and Nigeria.

Strong Revenue Growth

IDH reported consolidated revenue of EGP 3.5 billion for the first half of 2025, marking a 42% increase from the same period last year. This growth was driven by a 10% increase in test volumes and a 29% increase in average revenue per test.

Egypt Market Performance

In Egypt, IDH opened 49 new locations, leading to a 43% increase in top-line revenue to EGP 3 billion. The company also saw a 9% increase in test volumes and a 3% rise in patient volumes year-on-year.

Profitability Improvements

The gross profit margin expanded by 5 percentage points, and the adjusted EBITDA margin increased by 7 percentage points compared to last year. Adjusted net profit more than doubled year-on-year, yielding a margin of 16% versus 7% last year.

Saudi Arabia Market Expansion

Biolab KSA's revenue in Saudi Arabia surpassed the SAR 1 million mark, expanding by 31% versus the prior quarter, and reached SAR 1.9 million on a year-to-date basis.

Dividend Announcement

The Board of Directors approved a cash dividend of $0.017 per share for the year ended December 31, 2024, reflecting the company's strong financial performance and robust liquidity position.

Integrated Diagnostics Holdings (GB:IDHC) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

GB:IDHC Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 13, 2025	2025 (Q3)	- / -	0.008	―	―	―
Sep 02, 2025	2025 (Q2)	- / -	0.004	―	―	―
May 28, 2025	2025 (Q1)	- / -	0.167	―	―	―
Apr 17, 2025	2024 (Q4)	- / -	0.167	―	―	―
Nov 14, 2024	2024 (Q3)	- / <0.01	0.3	-97.33% (-0.29)	―	―
Aug 28, 2024	2024 (Q2)	- / <0.01	0.08	-95.00% (-0.08)	―	―
May 30, 2024	2024 (Q1)	- / 0.17	0.29	-42.41% (-0.12)	―	―
Mar 28, 2024	2023 (Q4)	- / 0.18	0.94	-80.85% (-0.76)	―	―
Nov 16, 2023	2023 (Q3)	- / 0.30	-0.735	140.82% (+1.03)	―	―
Aug 31, 2023	2023 (Q2)	- / 0.08	0.21	-61.90% (-0.13)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

GB:IDHC Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Sep 02, 2025	$0.47	$0.48	+2.13%
May 28, 2025	$0.34	$0.35	+2.94%
Apr 17, 2025	$0.31	$0.33	+6.45%
Nov 14, 2024	$0.41	$0.41	0.00%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Integrated Diagnostics Holdings PLC (GB:IDHC) report earnings?

Integrated Diagnostics Holdings PLC (GB:IDHC) is schdueled to report earning on Nov 13, 2025, TBA (Confirmed).

What is Integrated Diagnostics Holdings PLC (GB:IDHC) earnings time?

Integrated Diagnostics Holdings PLC (GB:IDHC) earnings time is at Nov 13, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is the P/E ratio of Integrated Diagnostics Holdings PLC stock?

The P/E ratio of Integrated Diagnostics Holdings is N/A.

What is GB:IDHC EPS forecast?

Currently, no data Available

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing